William Blair analyst Sami Corwin maintained a Buy rating on Krystal Biotech today. The company’s shares opened today at $183.38.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Corwin is a 5-star analyst with an average return of 28.8% and a 58.82% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and PTC Therapeutics.
Currently, the analyst consensus on Krystal Biotech is a Strong Buy with an average price target of $201.88.
KRYS market cap is currently $5.25B and has a P/E ratio of 37.58.
Read More on KRYS:
Disclaimer & DisclosureReport an Issue
- Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector
- Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments
- Buy Rating for Krystal Biotech Driven by Vyjuvek’s Expanded Label and Market Potential
- Krystal Biotech announces FDA approval of update VYJUVEK label
- 3 ‘Outperform’ Healthcare Stocks, According to AI Analyst, 9/10/25
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/PayPal%20Holdings%20Inc%20HQ%20photo-by%20bennymarty%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
